June 28th 2022
Expert oncologists Benjamin Levy, MD; Chaitali Nangia, MD; Jessica Donington, MD; Jonathan Wesley Riess, MD; Alexander Spira, MD; and Heather Wakelee, MD, review data from ASCO 2022 and updates in the management of NSCLC.
Expert oncologists Evan Y. Yu, MD; Andrew J. Armstrong, MD, MSc; Pedro C. Barata, MD, MSc; Tanya B. Dorff, MD; and Mary-Ellen Taplin, MD, review data from ASCO 2022 and discuss updates on the management of prostate cancer.
June 27th 2022
A panel of experts discuss how recent data from ASCO 2022 has changed the treatment landscape for small cell lung cancer.
Expert oncologists Andy Seidman, MD; Vijayakrishna Gadi, MD, PhD; Tiffany Traina, MD; William Gradishar, MD; and Stephanie Graff, MD, review data from ASCO 2022 and share updates in the management of HER2+ and HER2-low breast cancer.
Expert oncologists Hope S. Rugo, MD, FASCO; Aditya Bardia, MD, MPH; Komal Jhaveri, MD, FACP; Mark Pegram, MD; and Anne O'Dea, MD, review data from recent conferences and discuss updates in the management of HR+/HER2- breast cancer.
April 12th 2022
A panel of expert oncologists discusses updates in advanced non-small cell lung cancer and the evolving treatment landscape, and its impact on clinical practice.
March 31st 2022
Experts engage in discussion on patient profiles to review updated treatment approaches and sequencing in patients with HER2-positive metastatic breast cancer.
Expert panelists share insight on recent updates in the management of prostate cancer presented at several key conferences.
March 15th 2022
A panel of experts discuss renal cell carcinoma (RCC) using evidence-based data presented at the ASCO GU 2022 Annual Meeting this year.
March 9th 2022
Experts in gastrointestinal cancers review recent updates to the treatment landscape of advanced HCC and share insights on their impact on clinical practice.
January 26th 2022
Expert panelists reflect on the evolving landscape of HER2+ metastatic breast cancer by discussing the latest research and recent clinical trials.
January 24th 2022
Recommendations for applying information from clinical trials presented at oncology and hematology conferences in 2021 into routine clinical practice when managing patients with chronic lymphocytic leukemia.
January 11th 2022
Yi-Bin Chen, MD; Nelson J. Chao, MD, MBA; Hannah Choe, MD; and Sophie Paczesny, MD, PhD, review updates in the diagnosis and treatment of graft-vs-host disease.
December 23rd 2021
A panel of experts discuss myeloproliferative neoplasms, focusing primarily on myelofibrosis, and share their experiences treating these diseases.
A panel discussion on changing treatment landscape of diffuse large B-cell lymphoma (DLBCL) and how new data from ASH 2021 on CAR-T therapies and antibody-drug conjugate are likely to change frontline treatment and sequencing of therapies in relapsed and refractory DLBCL going forward.
Expert panelists discuss a number of recent updates in B-cell lymphoma, particularly mantle cell lymphoma, follicular lymphoma and marginal zone lymphoma, that were presented at key conferences in 2021.
Recommendations for treating 2 clinical cases of metastatic breast cancer with antibody-drug conjugates based on supporting data and their adoption into clinical practice.
Funding from Daiichi Sanyko. Content Developed Independently by OncLive.
December 22nd 2021
Expert perspectives on updates in EGFR-mutant resectable and advanced non–small cell lung cancer that were presented at key conferences in 2021 and how they have impacted the treatment landscape.
Experts in hematology/oncology review recent updates in the treatment of multiple myeloma presented at key conferences and share insight on the impact on clinical practice.
December 17th 2021
Medical oncologists and endocrinologists discuss approaches to the management of patients with differentiated thyroid cancer.
